Cargando…
Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors
Soft tissue tumors (STTs) include a range of benign and malignant tumors originating from soft tissues. Transarterial and percutaneous therapies are image-guided and minimally invasive approaches for managing primary and metastatic STTs. The objective of this review is to discuss transarterial and p...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381432/ https://www.ncbi.nlm.nih.gov/pubmed/37511864 http://dx.doi.org/10.3390/life13071485 |
_version_ | 1785080442389528576 |
---|---|
author | Shu, Chang Lim, Maria Fang, Adam |
author_facet | Shu, Chang Lim, Maria Fang, Adam |
author_sort | Shu, Chang |
collection | PubMed |
description | Soft tissue tumors (STTs) include a range of benign and malignant tumors originating from soft tissues. Transarterial and percutaneous therapies are image-guided and minimally invasive approaches for managing primary and metastatic STTs. The objective of this review is to discuss transarterial and percutaneous therapies by examining the current literature, including indications, patient selection, safety, and effectiveness. Transarterial therapies (e.g., transarterial bland embolization and transarterial chemoembolization) involve the delivery of either embolic or chemotherapeutic particles using a catheter into arteries feeding the tumor, resulting in localized tumor destruction. Percutaneous therapies (e.g., radiofrequency ablation, cryoablation, irreversible electroporation, laser ablation, and magnetic resonance-guided high-intensity focused ultrasound) involve the delivery of either hot or cold temperatures, electrical current, laser, or ultrasound to specifically target tumor cells. Both therapies have been shown to be safe and effective for reducing morbidity and local control of STTs, specifically in patients who are surgically inoperable or who are unresponsive to conventional therapies. Accurate diagnosis, staging, and histological subtype identification are crucial for treatment selection. A multidisciplinary approach, a thorough understanding of tissue anatomy and surrounding structures, as well as individualized strategies based on assessment are essential for optimal patient care. |
format | Online Article Text |
id | pubmed-10381432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103814322023-07-29 Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors Shu, Chang Lim, Maria Fang, Adam Life (Basel) Review Soft tissue tumors (STTs) include a range of benign and malignant tumors originating from soft tissues. Transarterial and percutaneous therapies are image-guided and minimally invasive approaches for managing primary and metastatic STTs. The objective of this review is to discuss transarterial and percutaneous therapies by examining the current literature, including indications, patient selection, safety, and effectiveness. Transarterial therapies (e.g., transarterial bland embolization and transarterial chemoembolization) involve the delivery of either embolic or chemotherapeutic particles using a catheter into arteries feeding the tumor, resulting in localized tumor destruction. Percutaneous therapies (e.g., radiofrequency ablation, cryoablation, irreversible electroporation, laser ablation, and magnetic resonance-guided high-intensity focused ultrasound) involve the delivery of either hot or cold temperatures, electrical current, laser, or ultrasound to specifically target tumor cells. Both therapies have been shown to be safe and effective for reducing morbidity and local control of STTs, specifically in patients who are surgically inoperable or who are unresponsive to conventional therapies. Accurate diagnosis, staging, and histological subtype identification are crucial for treatment selection. A multidisciplinary approach, a thorough understanding of tissue anatomy and surrounding structures, as well as individualized strategies based on assessment are essential for optimal patient care. MDPI 2023-06-30 /pmc/articles/PMC10381432/ /pubmed/37511864 http://dx.doi.org/10.3390/life13071485 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Shu, Chang Lim, Maria Fang, Adam Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors |
title | Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors |
title_full | Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors |
title_fullStr | Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors |
title_full_unstemmed | Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors |
title_short | Transarterial Embolization and Percutaneous Ablation of Primary and Metastatic Soft Tissue Tumors |
title_sort | transarterial embolization and percutaneous ablation of primary and metastatic soft tissue tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381432/ https://www.ncbi.nlm.nih.gov/pubmed/37511864 http://dx.doi.org/10.3390/life13071485 |
work_keys_str_mv | AT shuchang transarterialembolizationandpercutaneousablationofprimaryandmetastaticsofttissuetumors AT limmaria transarterialembolizationandpercutaneousablationofprimaryandmetastaticsofttissuetumors AT fangadam transarterialembolizationandpercutaneousablationofprimaryandmetastaticsofttissuetumors |